Correction: Synthesis and structure−activity relationships of DCLK1 kinase inhibitors based on a 5,11-dihydro‑6H‑benzo[e]pyrimido[5,4‑b][1,4]diazepin-6-one Scaffold (Journal of Medical Chemistry (2020) 63:14 (7817−7826) DOI: 10.1021/acs.jmedchem.0c00596)

_Page _from: 7819. Column 1, paragraph 3 should be corrected “Having failed to improve the selectivity via substitution of R₂ or R₃, we turned to exploration of the R₄ group. DCLK1 and LRRK2 possess a methionine gatekeeper residue (Met465 and Met1947, respectively), unlike ERK5, which has a leucine gatekeeper (Leu137). Examination of the ERK5-XMD8-92¹⁵ and the DCLK1-XMD8-85 cocrystal structures revealed that the R₄ methyl group is oriented toward the gatekeeper residue (Supporting Information Figure 1). Therefore, we hypothesized that varying the R₄ group may lead to improved selectivity against ERK5.” to: “Having failed to improve the selectivity via substitution of R₂ or R₃, we turned to exploration of the R₄ group. DCLK1 and LRRK2 possess a methionine gatekeeper residue (Met465 and Met1947, respectively), unlike ERK5, which has a leucine gatekeeper (Leu137). Examination of the ERK5-XMD8-92¹⁵ and the DCLK1-XMD8-85 cocrystal structures (Personal Communication, O. Patel & I. Lucet) revealed that the R₄ methyl group is oriented toward the gatekeeper residue (Supporting Information Figure 1). Therefore, we hypothesized that varying the R₄ group may lead to improved selectivity against ERK5.”